title: Increased serum chemerin concentration in patients with chronic pancreatitis.
abstract: BACKGROUND
  Chemerin is a potent chemoattractant for chemokine-like receptor 1 expressing cells and is involved in inflammatory and immune processes that play an important role in chronic pancreatitis.
  
  
  OBJECTIVE
  To test the hypothesis that serum chemerin concentration may be affected in chronic pancreatitis patients and that chemerin can influence the course of chronic pancreatitis by increasing profibrotic cytokine production.
  
  
  METHODS
  Serum concentrations of chemerin and the major cytokines involved in pancreatic fibrosis such as platelet-derived growth factor BB and transforming growth factor β-1 were determined by ELISA in samples from 40 nondiabetic and 28 diabetic male patients with chronic pancreatitis of alcoholic origin and 40 age-matched healthy controls.
  
  
  RESULTS
  Serum concentrations of chemerin were increased both in nondiabetic and diabetic chronic pancreatitis patients compared to controls. Moreover, in chronic pancreatitis patients a positive correlation was found between serum chemerin and platelet-derived growth factor BB as well as transforming growth factor β-1 concentrations.
  
  
  CONCLUSIONS
  The results indicate for the first time that: (a) chronic pancreatitis in humans is associated with an increased serum chemerin concentration and (b) serum chemerin concentration correlates with serum concentrations of the major profibrotic cytokines. Elevated level of chemerin, by stimulating macrophage infiltration of the pancreas, might lead to overproduction of platelet-derived growth factor BB and transforming growth factor β-1 and, consequently, to pancreatic fibrosis.
authors.affiliation: Department of Gastroenterology and Hepatology, Medical University of Gdansk, Gdansk, Poland.
authors.forename: Krystian
authors.initials: K
authors.lastname: Adrych
authors.forename: Magdalena
authors.initials: M
authors.lastname: Stojek
authors.forename: Marian
authors.initials: M
authors.lastname: Smoczynski
authors.forename: Tomasz
authors.initials: T
authors.lastname: Sledzinski
authors.forename: Szrok-Wojtkiewicz
authors.initials: SW
authors.lastname: Sylwia
authors.forename: Julian
authors.initials: J
authors.lastname: Swierczynski
mesh_terms: D000328:Adult; D000368:Aged; D000077214:Becaplermin; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000032:analysis; D016022:Case-Control Studies; D018925:Chemokines / Q000097:blood*; D003920:Diabetes Mellitus / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D019512:Pancreatitis, Alcoholic / Q000097:blood*; D020574:Proto-Oncogene Proteins c-sis / Q000097:blood; D052243:Resistin / Q000097:blood; D012720:Severity of Illness Index; D053773:Transforming Growth Factor beta1 / Q000097:blood
chemical_list: D018925:Chemokines; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin; D020574:Proto-Oncogene Proteins c-sis; C478630:RARRES2 protein, human; D052243:Resistin; D053773:Transforming Growth Factor beta1; D000077214:Becaplermin; D002097:C-Reactive Protein